Registry of Plasma Cell Dyscrasia
Official title: Longitudinal Data Registry of A Spectrum of Plasma Cell Dyscrasia With Long-term Follow-up
Run by Shanghai Zhongshan Hospital · NCT06760052 · Data updated 2026-11-12
This study is collecting and looking at health information from patients with plasma cell dyscrasia to better understand their disease and how it affects them.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 19 Years to 99 Years |
| Sex | All |
| Enrollment | 2000 (estimated) |
| Sponsor | Shanghai Zhongshan Hospital Academic / other |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Status | Recruiting |
| Started | March 1, 2023 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2028 |
| Registry record updated | August 3, 2026 |
| Trial ID | NCT06760052 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with a pathological diagnosis of PCD, such as multiple myeloma or MGUS, who have complete medical records from 2007 to 2027.
✕Probably not a fit
Patients with severe mental illness or those deemed unsuitable for inclusion by the investigator may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to collect and analyze clinical data on patients diagnosed with plasma cell dyscrasia (PCD) at Zhongshan Hospital, Fudan University. It includes both historical data from 2007 and ongoing prospective data collection to assess patient outcomes and characteristics. The study focuses on understanding the clinical and genetic features of PCD in the Chinese population and aims to explore the relationship between these characteristics and the disease's pathogenesis. By documenting real-world clinical practices, the study seeks to identify distinct clonal evolution patterns among various subtypes of PCD.
Why it matters
Potential benefit: If successful, this study could enhance understanding of plasma cell dyscrasia and improve patient management and treatment strategies.
How similar studies have gone: While this study builds on existing knowledge of plasma cell dyscrasia, it focuses on a specific population and may provide novel insights into the disease.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with pathological diagnosis of PCD \[e.g., symptomatic/asymptomatic multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), POEMS syndrome, light chain (AL) amyloidosis\] from 2007 to 2027 in Zhongshan Hospital or other collaborating centers. * Patients who had complete diagnostic, treatment, and follow-up records. * Patients with full comprehension and signature of the informed consent form (ICF) for participation. Exclusion Criteria: * Patients who refused to use reliable methods of contraception during pregnancy, lactation, or the age-appropriate period. * Patients who suffered from severe mental illness. * Patients who were deemed unsuitable for inclusion by the investigator.
Where it's running
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China Recruiting
Study contacts
- Study coordinator: Peng Liu, Ph.D
- Email: liu.peng@zs-hospital.sh.cn
- Phone: +862164041990 ext 2315
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
HDP-101 for relapsed or refractory multiple myeloma in Chinese patients
This trial will try HDP-101 to see if it is safe and can help control relapsed or refractory multiple myeloma in Chinese adults.
-
Abnormal menstrual bleeding in women on antithrombotic drugs after heart surgery
This study looks at whether women on blood thinners after heart surgery have abnormal menstrual bleeding and what factors might put some at higher risk.
-
Sleep and circadian care for ICU patients
This study tests a multicomponent sleep and circadian rhythm program in adult ICU patients to see if it helps keep daily rhythms and sleep better.
-
Thymalfasin added to standard care for adults with sepsis and immune dysfunction
This study tests whether thymosin alpha-1 helps restore immune function in adults with sepsis who have weakened immunity.
-
Multicenter group study of sepsis and ARDS in China
This study tests how sepsis and ARDS differ among adults across several Chinese hospitals and builds a biobank to understand why some patients do better or worse.
-
Adaptive intraoperative biopsy system for prostate cancer using imaging and metabolic feedback
Aiming to test a smart biopsy approach that combines preoperative imaging with real-time metabolic signals to guide where to take prostate biopsy cores for better precision in men suspected of prostate cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.